SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide a corporate update on Tuesday, August 3, 2021, after the close of the market.
Related Articles

Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019
SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer… […]

Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies
SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (?Aptose? or the ?Company?) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of ca… […]

Aptose to Present at September Investor Conferences
SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021: Click here to view original post… […]